Practical oncology,
Journal Year:
2022,
Volume and Issue:
23(4), P. 211 - 224
Published: Dec. 25, 2022
Liquid
biopsy
is
the
analysis
of
tumor
fragments
(entire
cells,
nucleic
acids,proteins)
in
hysiological
and
pathological
body
liquids.
This
technology
has
already
been
included
standard
procedures
detecting
secondary
mutations,
which
are
associate
with
acquired
drug
resistance.
a
promising
tool
for
early
cancer
detection,
evaluation
success
radical
surgery,
monitoring
residual
disease,
assessment
treatment
efficacy
etc.
Signal Transduction and Targeted Therapy,
Journal Year:
2024,
Volume and Issue:
9(1)
Published: Dec. 1, 2024
Cancer
has
a
high
mortality
rate
across
the
globe,
and
tissue
biopsy
remains
gold
standard
for
tumor
diagnosis
due
to
its
level
of
laboratory
standardization,
good
consistency
results,
relatively
stable
samples,
accuracy
results.
However,
there
are
still
many
limitations
drawbacks
in
application
tumor.
The
emergence
liquid
provides
new
ideas
early
prognosis
Compared
with
biopsy,
advantages
treatment
various
types
cancer,
including
non-invasive,
quickly
so
on.
Currently,
detection
received
widely
attention.
It
is
now
undergoing
rapid
progress,
it
holds
significant
potential
future
applications.
Around
now,
biopsies
encompass
several
components
such
as
circulating
cells,
DNA,
exosomes,
microRNA,
RNA,
platelets,
endothelial
cells.
In
addition,
advances
identification
indicators
have
significantly
enhanced
possibility
utilizing
clinical
settings.
this
review,
we
will
discuss
application,
challenges
some
common
tumors
from
perspective
diverse
systems
tumors,
look
forward
development
prospects
field
cancer
treatment.
Lab on a Chip,
Journal Year:
2023,
Volume and Issue:
23(5), P. 1258 - 1278
Published: Jan. 1, 2023
This
graphic
includes
droplet
generation
methods,
thermal
cycle
strategies,
signal
counting
approaches,
and
the
applications
in
fields
of
single-cell
analysis,
disease
diagnosis,
bacteria
detection,
virus
detection.
Cancers,
Journal Year:
2022,
Volume and Issue:
14(12), P. 2913 - 2913
Published: June 13, 2022
Cancer
arising
from
the
uterine
cervix
is
fourth
most
common
cause
of
cancer
death
among
women
worldwide.
Almost
90%
cervical
mortality
has
occurred
in
low-
and
middle-income
countries.
One
major
aetiologies
contributing
to
persistent
infection
by
cancer-causing
types
human
papillomavirus.
The
disease
preventable
if
premalignant
lesion
detected
early
managed
effectively.
In
this
review,
we
outlined
standard
guidelines
that
have
been
introduced
implemented
worldwide
for
decades,
including
cytology,
HPV
detection
genotyping,
immunostaining
surrogate
markers.
addition,
staging
system
used
classify
premalignancy
malignancy
cervix,
as
well
safety
efficacy
various
treatment
modalities
clinical
trials
cancers,
are
also
discussed.
millennial
world,
advancements
computer-aided
technology,
robotic
modules
artificial
intelligence
(AI),
incorporated
into
screening,
diagnostic,
platforms.
These
innovations
reduce
dependence
on
specialists
technologists,
work
burden
time
incurred
sample
processing.
However,
concerns
over
practicality
these
remain,
due
high
cost,
lack
flexibility,
judgment
a
trained
professional
currently
not
replaceable
machine.
Cancer Medicine,
Journal Year:
2023,
Volume and Issue:
12(17), P. 17592 - 17602
Published: July 26, 2023
Abstract
Background
HPV
infection
can
cause
cancer,
and
standard
treatments
often
result
in
recurrence.
The
extent
to
which
liquid
biopsy
using
circulating
tumor
DNA
(HPV
ctDNA)
be
used
as
a
promising
marker
for
predicting
recurrence
HPV‐related
cancers
remains
validated.
Here
we
conducted
systematic
review
meta‐analysis
assess
its
effectiveness
treatment
response.
Methods
We
literature
search
of
online
databases,
including
PubMed,
Embase,
Scopus,
the
Cochrane
Library,
up
December
2022.
goal
was
identify
survival
studies
that
evaluated
potential
plasma
ctDNA
at
baseline
end‐of‐treatment
(EoT)
related
cancers.
Hazard
ratios
were
estimated
directly
from
models
or
extracted
Kaplan–Meier
plots.
Results
pooled
effect
presence
on
disease
HR
=
7.97
(95%
CI:
[3.74,
17.01]).
Subgroup
analysis
showed
risk
2.17
[1.07,
4.41])
baseline‐positive
cases
13.21
[6.62,
26.36])
EoT‐positive
cases.
Significant
associations
also
observed
between
oropharyngeal
squamous
cell
carcinoma
(HR
12.25
[2.62,
57.36]))
cervical
cancer
4.60
[2.08,
10.17]))
ctDNA‐positive
patients.
Conclusions
study
found
detection
predict
rate
relapse
after
treatment,
with
post‐treatment
measurement
being
more
effective
than
assessment.
could
surrogate
incorporated
other
methods
detecting
residual
disease.
Frontiers in Cellular and Infection Microbiology,
Journal Year:
2024,
Volume and Issue:
14
Published: Feb. 28, 2024
Cervical
cancer
is
the
third
most
common
threatening
women’s
health
globally,
and
high-risk
human
papillomavirus
(HR-HPV)
infection
main
cause
of
cervical
worldwide.
Given
recurrent
nature
HR-HPV
infection,
accurate
screening
essential
for
its
control.
Since
commonly
used
polymerase
chain
reaction
(PCR)
technique
limited
by
professional
equipment
personnel,
convenient
ultrasensitive
detection
methods
are
still
highly
needed.
As
new
molecular
methods,
nucleic
acid
amplification-based
biosensors
have
advantages
high
sensitivity,
rapid
operation,
portability,
which
helpful
point-of-care
testing
in
rural
remote
areas.
This
review
summarized
based
on
a
variety
amplification
strategies
involved
improved
PCR,
loop-mediated
isothermal
amplification,
recombinase
hybridization
reaction,
catalyzed
hairpin
assembly,
CRISPR/Cas
systems.
In
combination
with
microfluidic
technology,
lateral
flow
assays,
electrochemical
analysis
other
sensing
technologies,
throughput,
short
response
time,
sensitivity
easy
operation
field.
Although
there
shortcomings,
such
as
cost
poor
reproducibility,
this
approach
will
be
suitable
on-site
or
auxiliary
clinical
diagnosis
complex
environments
areas
future.
Journal of Medical Virology,
Journal Year:
2025,
Volume and Issue:
97(3)
Published: March 1, 2025
Oral
HPV
DNA
and
circulating
tumor
(ct)
in
plasma
were
evaluated
as
potential
biomarkers
for
HPV-associated
head
neck
cancer
(HNC).
Samples
from
HNC
patients
(n
=
132),
including
23
oropharyngeal
cancers
(OPC),
non-HNC
controls
10)
analyzed.
status
was
determined
using
a
multiplex
bead-based
test
(E7-MPG)
applied
to
formalin-fixed
paraffin-embedded
(FFPE)
tissues
90),
141),
gargle
samples
oral
swabs
142).
detected
25.8%
of
tissues,
12%
samples,
20.6%
gargles
7%
with
HPV16
the
most
prevalent
genotype.
Among
OPC
cases,
found
71.4%
FFPE
samples.
High
concordance
observed
between
paired
(91.3%)
or
(95.2%),
moderate
(59.1%).
Gargle
alone
demonstrated
100%
detection
rate
HPV16-positive
OPC,
regardless
cT
stage,
outperforming
(86.7%).
Combined
analyses
all
HPV-positive
cases
(7/7)
at
early
cT1
stage.
These
findings
highlight
limited
involvement
non-oropharyngeal
compared
support
minimally
invasive
diagnostic
tools
detecting
OPC.
Cureus,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 16, 2025
Anal
cancer
has
shown
increasing
incidence
and
death
rates
in
recent
years
despite
their
lower
rate
the
general
population.
Various
risk
factors
contribute
to
this
upward
trend,
with
sexual
playing
a
notable
role.
Additionally,
there
is
strong
correlation
between
patients'
survival
clinical
outcomes
tumor
stages,
underscoring
importance
of
developing
effective
screening
methods
for
anal
cancer,
particularly
high-risk
groups.
The
well-established
link
human
papillomavirus
(HPV)
infection
tumors,
combined
success
cervical
programs,
led
some
similarities
strategies.
However,
absence
established
guidelines
indicates
need
further
research
assess
efficacy
these
across
different
populations.
Such
would
enhance
knowledge,
awareness,
motivation
participation
programs.
In
review,
we
will
discuss
various
approaches,
including
characteristics,
novel
biomarkers,
molecular
methods,
as
well
prevention
strategies
existing
limitations
screening.
Scientific Reports,
Journal Year:
2025,
Volume and Issue:
15(1)
Published: April 3, 2025
Liquid
biopsies,
which
analyze
circulating
tumor
cells
or
cell-free
DNA
(ctDNA)
from
blood,
have
emerged
as
promising
cancer
detection
and
monitoring
tools.
Specifically,
human
papillomavirus
(HPV)
(cf)
is
gaining
recognition
a
prognostic
marker
in
high-risk
HPV-related
cancers.
However,
detecting
markers
for
cervical
(CC)
requires
highly
sensitive
techniques
to
quantify
HPV
DNA.
This
study
aimed
evaluate
the
use
of
droplet
digital
PCR
(ddPCR),
technique,
quantifying
patients,
both
at
baseline
(before
chemo-
radiotherapy)
during
follow-up,
assess
its
utility
marker.
Blood
samples
were
collected
60
patients
(Stages
I-IV)
AIIMS,
New
Delhi,
three
months
post-treatment.
Samples
10
healthy
controls
also
included.
Plasma
was
separated
stored
-
80
°C,
cfDNA
extracted
1
ml
plasma.
The
presence
types,
HPV16
HPV18,
35
assessed
using
ddPCR.
median
concentration
9.35
ng/µL
baseline,
decreased
7
after
treatment.
In
controls,
6.95
ng/µL.
ddPCR
screening
showed
that
rates
HPV18
45.71%
82.86%,
respectively.
A
significant
correlation
observed
between
cf
levels
size,
suggesting
potential
biomarker
disease
burden.
Clinical Chemistry,
Journal Year:
2024,
Volume and Issue:
70(1), P. 285 - 296
Published: Jan. 1, 2024
Abstract
Background
More
than
95%
of
cervical
cancers
and
their
precancerous
lesions
are
caused
by
human
papillomavirus
(HPV).
Cell-free
(cf)
HPV
DNA
detection
in
blood
samples
may
serve
as
a
monitoring
tool
for
cancer.
Methods
In
our
methodological
study,
an
panel
simultaneous
24
types
using
mass
spectrometry-based
analysis
was
developed
liquid
biopsy
approaches
tested
on
positive
cell
lines,
plasmid
controls,
high-grade
squamous
intraepithelial
(HSIL)
smear
(n
=
52).
It
validated
cfDNA
40)
cancer
patients.
Results
The
showed
proficient
results
lines
viral
plasmids
with
limit
1
IU
(international
units)/µL
HPV16/18
10GE/µL
HPV11/31/33/39/45/51/52/58/59
specificity
100%
the
types.
samples,
detected
sensitivity
98.14%.
overall
agreement
between
new
clinical
records
97.2%
(κ
0.84).
cfDNA,
26/40
(65.0%)
any
type,
most
infections
due
to
hrHPV
(24/26).
were
found
all
FIGO
stages,
highest
positivity
ratio
III
IV.
Even
lowest
stage,
I,
had
12/23
(52.2%)
patients
plasma
status.
Conclusions
This
proof-of-concept
paper
shows
that
described
assay
produces
reliable
detecting
multiplex
high
both
cohorts.
potential
biopsy-based
applications
progression.
